Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

21 July 2017 CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of orphan-drug exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of hereditary angioedema (HAE) attacks.

> Read More
19 July 2017 FDA Accepts CSL Behring’s Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental Biologics License Application (BLA) for Hizentra® [Immune globulin subcutaneous (Human) 20% liquid] for the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

> Read More
12 July 2017 New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B

CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates in both adult and paediatric patients with haemophilia B.

> Read More
11 July 2017 CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken Leadership Awards.

> Read More
10 July 2017 New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A

CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the prophylaxis and on-demand settings.

> Read More
Page 1 of 7 Next | Last

Share
LinkedIn Twitter Facebook Google+